Roche Tasmar for Parkinson's will be available by March following Jan. 29 approval.
Executive Summary
ROCHE TASMAR 200 MG T.I.D. REDUCES "OFF" TIME BY THREE HOURS from a baseline of 5.9 hours, according to data from a U.S./Canadian study included in labeling for the Parkinson's disease therapy approved Jan. 29. The 100 mg t.i.d. dose of Tasmar (tolcapone) reduced "off" time by two hours from a 6.4 hour baseline and placebo reduced it by 1.2 hours from 6.2 hours.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: